Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Fluzone Vaccines (2013-2014)
NCT01946438Phase 4Completed
- Sponsor
- Sanofi
- Start
- Sep 2013
- Primary completion
- Dec 2013
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated), Fluzone Intradermal and trivalent inactivated influenza vaccine high-dose in influenza (4 arms), sponsored by Sanofi. Primary endpoint: Solicited Injection-Site and Systemic Reactions. Started Sep 2013; status: completed.
02
Drugs
Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated)Fluzone Intradermaltrivalent inactivated influenza vaccine high-dose
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01946438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01946438.